Three-Year CD4/CD8 Ratio Recovery After Initiation of Dual Versus Triple Integrase Inhibitor–Based Therapy in Naïve Adults With HIV

Key Points

• This research aims to compare immune recovery based on the CD4/CD8 ratio following two different treatment regimens in naïve HIV adults.
• 21,233 adults from the Spanish HIV Research Network were analyzed.
• Propensity score-matching was used to compare two integrase inhibitor therapies, 2DR and 3DR.
• Data were evaluated for CD4/CD8 ratio normalization at three years.
• No detectable differences in CD4/CD8 normalization between dolutegravir-based 2DR and integrase inhibitor-based 3DR.
• Similar immune recovery rates were observed across all measured cutoffs at three years.